Key Facts Surrounding This News Item
- TORC had returned 0.00% year-to-date leading up to today’s news, versus a +5.40% return from the benchmark S&P 500 during the same period.
More Info About resTORbio, Inc. (TORC)
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases and conditions in the United States. It is developing TORC1 inhibitor class of pharmaceutical products, including RTB101 and RTB101 with everolimus that are in Phase IIb clinical trial for the treatment of respiratory tract infections; and that have completed Phase I clinical trials for the treatment of heart failure with preserved ejection fraction and autophagy-related neurodegenerative diseases, as well as other infections, such as urinary tract infections. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc. View our full TORC ticker page with ratings, news, and more.